We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Among the top pharmaceutical companies in the world specializing in oncology, Ipsen seeks to address the challenges posed by the most difficult-to-treat cancers. Ipsen’s decades of work in oncology has generated differentiated treatments in indications with high unmet needs, including prostate cancer, breast cancer, neuroendocrine tumors, medullary and differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, follicular lymphoma, epithelioid sarcoma and pancreatic cancer.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

For more information, visit www.ipsen.com

ALLSC-ALL-003291
ALLSC-AT-000008
23/01/2024